Yifan Zhai

Yifan Zhai

Chief Tech/Sci/R&D Officer at ASCENTAGE PHARMA GROUP INTERNATIONAL

Net worth: 148 M $ as of 30/04/2024

62 year
Health Technology
Consumer Services
Health Services

Profile

Yifan Zhai is a Chief Medical Officer at Ascentage Pharma Group International Co., Ltd.
She previously held positions as Director-Pharmacology Department at Exelixis, Inc., President at HealthQuest, Inc., Chief Scientific Officer at Celladon Corp.
and Oncomax Acquisition Corp.
She was also President of The Chinese Biopharmaceutical Association.
She worked as a Principal at Human Genome Sciences, Inc. and Bayer Pharmaceuticals Corp.
Zhai holds a doctorate degree from Michigan State University and Sun Yat-Sen University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
27/10/2023 64,585,929 ( 22.25% ) 148 M $ 30/04/2024

Yifan Zhai active positions

CompaniesPositionStart
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Tech/Sci/R&D Officer 01/07/2013
All active positions of Yifan Zhai

Former positions of Yifan Zhai

CompaniesPositionEnd
The Chinese Biopharmaceutical Association President 01/01/2010
Chief Tech/Sci/R&D Officer 01/01/2010
Oncomax Acquisition Corp. Chief Tech/Sci/R&D Officer 01/01/2007
President 01/01/2005
EXELIXIS, INC. Corporate Officer/Principal 01/01/2003
See the detail of Yifan Zhai's experience

Training of Yifan Zhai

Michigan State University Doctorate Degree
Sun Yat-Sen University Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Yifan Zhai's experience

Connections

100 +

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
EXELIXIS, INC.

Health Technology

ASCENTAGE PHARMA GROUP INTERNATIONAL

Health Technology

Private companies6

Health Technology

Health Technology

Bayer Pharmaceuticals Corp.

Health Services

The Chinese Biopharmaceutical Association

Oncomax Acquisition Corp.

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW